Evidence map›Paper›PMID 40181542›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

An engineered mitoCBE facilitates efficient mitochondrial DNA editing and modified mitochondrial transfer.

Jie Liu, Jun Chen, Shisheng Huang, Junfan Guo, Xiangyang Li, Ying Yan, Ruijing Chen, Guanglei Li, Ming Liu, Jiao Wei and 2 more

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jie LiuGraduate School of Guangzhou Medical University, Guangzhou 510150, China; Guangzhou National Laboratory, Guangzhou 510005, China.
Jun ChenDepartment of Endocrinology and Metabolism, Qilu Hospital, Shandong University, Jinan 250012, China. Electronic address: junchen@email.sdu.edu.cn.
Shisheng HuangZhejiang Lab, Hangzhou, Zhejiang 311121, China.
Junfan GuoSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Xiangyang LiThe First Affiliated Hospital, and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China.
Ying YanSchool of Medicine, Tongji University, Shanghai 200092, China.
Ruijing ChenThe First Clinical Medical College, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Guanglei LiZhejiang Lab, Hangzhou, Zhejiang 311121, China.
Ming LiuThe First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China.
Jiao WeiNinth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China. Electronic address: drweijiao@shsmu.edu.cn.
Xingxu HuangGuangzhou National Laboratory, Guangzhou 510005, China; Zhejiang Lab, Hangzhou, Zhejiang 311121, China; The First Affiliated Hospital, and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China. Electronic address: huangxx@shanghaitech.edu.cn.
Yunbo QiaoNinth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China; Shanghai Institute of Precision Medicine, Shanghai 200125, China. Electronic address: ybqiao@shsmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Double-stranded DNA cytosine deaminase DddA orthologs from multiple types of bacteria have been fused with the transcription-activator-like effector system for mitochondrial DNA (mtDNA) base editing, while the efficiencies remain limited and its nuclear off-targeting activity cannot be ignored yet. Here we identified a DddA ortholog from Burkholderia gladioli (BgDddA) and generated nuclear or mtDNA cytosine base editors (mitoCBEs), exhibiting higher C⋅G-to-T⋅A editing frequencies compared with canonical DdCBE, and fusion with transactivator Rta remarkably improved editing efficiencies by up to 6.4-fold at non-TC targets. Referring to DddA11, we further introduced six substitutions into BgDddA and generated mitoCBE3.2, which efficiently induced disease-associated mtDNA mutations in mouse and human cell lines at both TC and non-TC targets with efficiency reaching up to 99.2%. Using mitoCBE3.2, single clones containing homoplasmic mtDNA mutations or premature stop codons associated with human diseases were generated, and the functions of these mutations have been evaluated upon the treatment of reactive oxygen species inducers. Importantly, mitochondria harboring these homoplasmic mutations were transplanted into wild-type cells, enabling precise base conversions, without the risk of nuclear gene off-targets. Thus, we have engineered an efficient mitoCBE using BgDddA, facilitating mitochondrial disease modeling and potential mutation correction with the aid of mitochondrial transplantation.

Indexed as

DNA, MitochondrialGene EditingMitochondriaAnimalsCell LineHumansMiceMutationReactive Oxygen SpeciesDNA, MitochondrialReactive Oxygen SpeciesBgDddAcytosine base editorDdCBEmitoCBEmitochondrial transplantationmutationoff-target

Identifiers

PMID40181542
PMCPMC12266020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.